Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Travere Therapeutics Inc | TVTX | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 6.26 | 04:23:31 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 6.26 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 5.12 - 19.5424 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 6.26 | USD |
Travere Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 476.38M | 76.10M | - | 145.24M | -111.4M | -1.46 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Travere Therapeutics News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TVTX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 5.33 | 6.56 | 5.235 | 5.84 | 1,367,703 | 0.93 | 17.45% |
| 1 Month | 7.07 | 7.26 | 5.12 | 6.02 | 1,450,681 | -0.81 | -11.46% |
| 3 Months | 8.43 | 9.03 | 5.12 | 7.14 | 1,263,422 | -2.17 | -25.74% |
| 6 Months | 6.95 | 10.27 | 5.12 | 7.60 | 1,421,585 | -0.69 | -9.93% |
| 1 Year | 16.86 | 19.5424 | 5.12 | 9.97 | 1,404,518 | -10.60 | -62.87% |
| 3 Years | 23.56 | 31.65 | 5.12 | 16.84 | 1,094,123 | -17.30 | -73.43% |
| 5 Years | 25.15 | 33.0899 | 5.12 | 17.52 | 1,019,710 | -18.89 | -75.11% |
Travere Therapeutics Description
| Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on the development and commercialization of therapies for people living with rare diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often lead to end-stage kidney disease. |
